Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 3/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5093242 | 1.00 | CYP1A2 (0.46) | CYP1A2CYSLTR1CYSLTR2NCF1NOS2 | |
| SCHEMBL6535913 | 0.85 | CYSLTR1 (0.46) | CYP1A2CYSLTR1CYSLTR2NCF1NOS2 | |
| SCHEMBL9287417 | 0.85 | CYP1A2 (0.49) | CYP1A2CYSLTR1CYSLTR2NCF1NOS2 | |
| SCHEMBL1115865 | 0.81 | CYP1A2 (0.46) | CYP1A2CYSLTR1CYSLTR2NCF1NOS2 | |
| SCHEMBL8754663 | 0.81 | CYSLTR1 (0.46) | CYP1A2CYSLTR1CYSLTR2NCF1NOS2 | |
| SCHEMBL5510083 | 0.81 | CYSLTR1 (0.46) | CYP1A2CYSLTR1CYSLTR2NCF1NOS2 | |
| SCHEMBL8754671 | 0.81 | CYSLTR1 (0.46) | CYP1A2CYSLTR1CYSLTR2NCF1NOS2 | |
| SCHEMBL6525088 | 0.80 | CYSLTR1 (0.52) | CYP1A2CYSLTR1CYSLTR2NCF1NOS2 | |
| SCHEMBL17500352 | 0.80 | CYSLTR1 (0.49) | CYP1A2CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL17227498 | 0.79 | CYSLTR1 (0.50) | CYP1A2CYSLTR1CYSLTR2NCF1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712485-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11389464-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3939972-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | Molecular Insight Pharmaceuticals, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210338850-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| EP-3545978-B1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARM INC (US) | 2021-09-08 | — | — | EP | disclosed |
| US-10898598-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3719024-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | Mars, Incorporated (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200246362-A1 | Arginase Inhibitors as Therapeutics | MARS, INCORPORATED | 2020-08-06 | — | — | US | disclosed |
| CN-106008569-B9 | Borate as arginase inhibitor and composition and application thereof | 马尔斯公司 | 2020-05-22 | — | — | CN | disclosed |
| EP-3034509-B1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS INC (US) | 2020-04-22 | — | — | EP | disclosed |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2012-05-24 | — | — | US | disclosed |
| WO-2012058065-A1 | BORONATES AS ARGINASE INHIBITORS | MARS INCORPORATED (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| WO-2012033525-A2 | P53-MDM2 ANTAGONISTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011133653-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED (US) | 2011-10-27 | — | — | WO | disclosed |
| EP-1351940-B1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF PROTOZOAN AND RETROVIRUS CO-INFECTIONS | INST RECH DEVELOPPEMENT IRD (FR) | 2007-07-25 | — | — | EP | disclosed |
| EP-1351940-A1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF PROTOZOAN AND RETROVIRUS CO-INFECTIONS | Institut de Recherche pour le Développement ( IRD) (FR) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002057238-A1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF PROTOZOAN AND RETROVIRUS CO-INFECTIONS | INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD) (FR) | 2002-07-25 | — | — | WO | disclosed |
| US-5811422-A | USEFUL FOR TREATING VIRAL INFECTIONS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-09-22 | — | — | US | disclosed |
| US-5610294-A | VIRAL TREATMENT | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11389464-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | CYP1A2 423/4885CYSLTR1 1183/4885CYSLTR2 1362/4885 |
| US-20210338850-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | PSMA2, PSMA5, PSMA1 | CYP1A2 2286/4885CYSLTR1 2047/4885CYSLTR2 1610/4885 |
| US-10898598-B2 | Triazine based radiopharmaceuticals and radioimaging agents | PSMA2, PSMA5, PSMA1 | CYP1A2 2286/4885CYSLTR1 2047/4885CYSLTR2 1610/4885 |
| US-11712485-B2 | Triazine based radiopharmaceuticals and radioimaging agents | PSMA2, PSMA5, PSMA1 | CYP1A2 2286/4885CYSLTR1 2047/4885CYSLTR2 1610/4885 |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | CYP1A2 423/4885CYSLTR1 1183/4885CYSLTR2 1362/4885 |
| US-20200246362-A1 | Arginase Inhibitors as Therapeutics | ARG1, ARG2, PRMT1 | CYP1A2 423/4885CYSLTR1 1183/4885CYSLTR2 1362/4885 |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | CYP1A2 490/4885CYSLTR1 2092/4885CYSLTR2 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.